Literature DB >> 19185898

High rate of fatigue and abdominal symptoms 2 years after an outbreak of giardiasis.

K Mørch1, K Hanevik, G Rortveit, K A Wensaas, N Langeland.   

Abstract

The aim of this study was to evaluate the prevalence of fatigue and abdominal symptoms 2 years after Giardia lamblia infection. All 1262 cases who had Giardia-positive stool samples during an outbreak in 2004 in Norway received a questionnaire in 2006 asking about fatigue and abdominal symptoms. Fatigue was reported by 41%, whereas 38% reported abdominal symptoms, and there was a highly significant association between these symptoms. Increasing age was a highly significant risk factor for fatigue. The symptoms were not due to chronic infection in this cohort. Our data warrant further investigations into the late effects of giardiasis.

Entities:  

Mesh:

Year:  2009        PMID: 19185898     DOI: 10.1016/j.trstmh.2009.01.010

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  14 in total

1.  Hospitalization of Cuban children for giardiasis: a retrospective study in a paediatric hospital in Havana.

Authors:  A A Escobedo; P Almirall; M Alfonso; Y Salazar; I Avila; S Cimerman; F A Núñez; I V Dawkins
Journal:  Ann Trop Med Parasitol       Date:  2011-01

2.  Giardia Alters Commensal Microbial Diversity throughout the Murine Gut.

Authors:  N R Barash; J G Maloney; S M Singer; S C Dawson
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

Review 3.  Extra-intestinal and long term consequences of Giardia duodenalis infections.

Authors:  Marie C M Halliez; André G Buret
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

4.  Chronic fatigue syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course.

Authors:  Kristine Mørch; Kurt Hanevik; Ann C Rivenes; Jørn E Bødtker; Halvor Næss; Bjarte Stubhaug; Knut-Arne Wensaas; Guri Rortveit; Geir E Eide; Trygve Hausken; Nina Langeland
Journal:  BMC Gastroenterol       Date:  2013-02-12       Impact factor: 3.067

5.  Chronic fatigue syndrome after Giardia enteritis: clinical characteristics, disability and long-term sickness absence.

Authors:  Halvor Naess; Morten Nyland; Trygve Hausken; Inghild Follestad; Harald I Nyland
Journal:  BMC Gastroenterol       Date:  2012-02-08       Impact factor: 3.067

6.  Phylogeny-directed search for murine leukemia virus-like retroviruses in vertebrate genomes and in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome and prostate cancer.

Authors:  Jonas Blomberg; Ali Sheikholvaezin; Amal Elfaitouri; Fredrik Blomberg; Anna Sjösten; Johan Mattson Ulfstedt; Rüdiger Pipkorn; Clas Källander; Christina Ohrmalm; Göran Sperber
Journal:  Adv Virol       Date:  2011-09-04

7.  Post-infection symptoms following two large waterborne outbreaks of Cryptosporidium hominis in Northern Sweden, 2010-2011.

Authors:  Moa Rehn; Anders Wallensten; Micael Widerström; Mikael Lilja; Maria Grunewald; Stephan Stenmark; Malin Kark; Johan Lindh
Journal:  BMC Public Health       Date:  2015-06-04       Impact factor: 3.295

8.  Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice.

Authors:  Tzu-Ling Chen; Shin Chen; Hsiu-Wei Wu; Tsung-Chun Lee; Yen-Zhen Lu; Li-Ling Wu; Yen-Hsuan Ni; Chin-Hung Sun; Wei-Hsuan Yu; Andre G Buret; Linda Chia-Hui Yu
Journal:  Gut Pathog       Date:  2013-08-30       Impact factor: 4.181

9.  Severity of Giardia infection associated with post-infectious fatigue and abdominal symptoms two years after.

Authors:  Kristine Mørch; Kurt Hanevik; Guri Rortveit; Knut-Arne Wensaas; Geir Egil Eide; Trygve Hausken; Nina Langeland
Journal:  BMC Infect Dis       Date:  2009-12-15       Impact factor: 3.090

10.  Characteristics and risk factors for symptomatic Giardia lamblia infections in Germany.

Authors:  Werner Espelage; Matthias an der Heiden; Klaus Stark; Katharina Alpers
Journal:  BMC Public Health       Date:  2010-01-28       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.